

In re Application of:
Albani and Prakken
Application No.: 09/828,574
Filed: April 6, 2001

MAR 09 2005
Attorney Docket No.: UCSD1310-1

PATENT

Title: STRESS PROTEINS AND PEPTIDES AND METHODS OF USE THEREOF
PENDING CLAIMS

CLAIMS FOR DISCUSSION WITH EXAMINER NAVARRO

1. (Currently Amended) An isolated HLA pan-DR-binding peptide comprising a stress protein fragment that binds to a MHC class II molecule, wherein the fragment is up to having about 11 to 20 ~~30~~ amino acid residues in length and comprises a core sequence of wherein at least 9 amino acid residues of the peptide consist of a sequence as set forth in SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:23, flanked at either each end by at least one amino acid, wherein the core sequence has an amino acid sequence selected from the group consisting of LSEKKISSI (SEQ ID NO:18), PQDAYVLLS (SEQ ID NO:20), LTTEAVVAD (SEQ ID NO:21), PLTTEAVVA (SEQ ID NO:22), and LTTEAVVVT (SEQ ID NO:23), and wherein the fragment comprises a naturally occurring amino acid sequence.

5. An isolated peptide having about 11 to 20 amino acid residues and according to claim 1, wherein the amino acid sequence of the peptide is having at least 70% identical identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9.

6. An isolated peptide having about 11 to 20 amino acid residues and according to claim 1, wherein the amino acid sequence of the peptide is having at least 80% identical identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9.

7. An isolated peptide having about 11 to 20 amino acid residues and according to claim 1, wherein the amino acid sequence of the peptide is having at least 90% identical identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9.

8. An isolated peptide having about 11 to 20 amino acid residues and according to claim 1, wherein the amino acid sequence of the peptide is having at least 95% identical identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9.

BEST AVAILABLE COPY

C:\Documents and Settings\anovom\My Documents\Word\Gray Cap\UCSD1310-UCSD1310-1 Claims for Discussion with Examiner Navarro.doc

In re Application of:

Albani and Prakken

Application No.: 09/828,574

Filed: April 6, 2001

Title: STRESS PROTEINS AND PEPTIDES AND METHODS OF USE THEREOF
PENDING CLAIMS

PATENT

MAR 09 2005 Attorney Docket No.: UCSD1310-1

9. ~~An isolated peptide according to claim 5, wherein the amino acid sequence of the peptide has having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9.~~

17. (Canceled) ~~An isolated peptide according to claim 1, wherein the fragment is 13 to about 30 amino acids in length.~~

18. (Canceled) ~~An isolated peptide according to claim 17, wherein the fragment is about 15 to about 25 amino acids in length.~~

19. (Currently Amended) An isolated peptide according to claim 17 1, wherein the fragment peptide is about 15 to about 20 amino acids in length.

20. An isolated peptide according to claim 1, wherein the peptide has one or more D- amino acid residues.

21. (Currently Amended) An isolated peptide according to claim 8 1 that contains a conservative amino acid substitution at least one amino acid position in the peptide.

24. A pharmaceutical composition comprising a peptide according to claim 1 in a pharmaceutically acceptable carrier.

25 - 32 (Cancelled)

33. A composition comprising a pharmaceutically acceptable carrier and an isolated peptide comprising a ~~fragment of a stress protein that binds to a MHC class II molecule, wherein the fragment is up to about 30 amino acid residues in length and comprises a core sequence flanked at either end by at least one amino acid, wherein the core sequence has an amino acid sequence selected from the group consisting of LSEKKISSI (SEQ ID NO:18), FQDAYVLLS (SEQ ID NO:20), LTTEAVVAD (SEQ ID NO:21), FLTTEAVVA (SEQ ID NO:22), and LTTEAEVVVT (SEQ ID NO:23), and wherein the fragment comprises a naturally occurring amino acid sequence according to claim 1.~~

In re Application of:
Albani and Prakken
Application No.: 09/828,574
Filed: April 6, 2001

PATENT
Attorney Docket No.: UCSD1310-1

Title: STRESS PROTEINS AND PEPTIDES AND METHODS OF USE THEREOF
PENDING CLAIMS

38. (Currently Amended) A composition according to claim ~~34~~ 33, wherein the isolated peptide has an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 7, 8, and 9.

64. (Currently Amended) An isolated peptide according to claim 1 or 9, wherein the peptide that is glycosylated.

67. (Canceled) ~~An isolated peptide, wherein the amino acid sequence of the peptide consists essentially of the amino acid sequence SEQ ID NO: 6.~~

68. (Currently Amended) An isolated peptide ~~of claim 67~~, wherein the amino acid sequence of the peptide consists of the amino acid sequence SEQ ID NO: 6.

69. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier and an isolated peptide, wherein the amino acid sequence of the peptide consists essentially of the amino acid sequence of SEQ ID NO: 6.

70. (Canceled) ~~The composition of claim 69, wherein the amino acid sequence of the peptide consists of the amino acid sequence of SEQ ID NO: 6.~~

71. (New) An isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence SEQ ID NO: 2.

72. (New) A composition comprising a pharmaceutically acceptable carrier and an isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence of SEQ ID NO: 2.

73. (New) An isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence SEQ ID NO: 3.

In re Application of:
Albani and Prakken
Application No.: 09/828,574
Filed: April 6, 2001

PATENT
Attorney Docket No.: UCSD1310-1

Title: STRESS PROTEINS AND PEPTIDES AND METHODS OF USE THEREOF
PENDING CLAIMS

74. (New) A composition comprising a pharmaceutically acceptable carrier and an isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence of SEQ ID NO: 3.

RECEIVED
CENTRAL FAX CENTER

In re Application of:
Albani and Prakken
Application No.: 09/828,574
Filed: April 6, 2001
Title: STRESS PROTEINS AND PEPTIDES AND METHODS OF USE THEREOF

MAR 09 2005

PATENT
Attorney Docket No.: UCSD1310-1

PENDING CLAIMS

CLAIMS FOR DISCUSSION WITH EXAMINER NAVARRO

1. (Currently Amended) An isolated peptide having about 11 to 20 amino acid residues wherein at least 9 amino acid residues of the peptide consist of a sequence as set forth in SEQ ID NO:18, SEQ ID NO:20 or SEQ ID NO:23.

5. (Currently Amended) An isolated peptide having about 11 to 20 amino acid residues and having at least 70% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9.

6. (Currently Amended) An isolated peptide having about 11 to 20 amino acid residues and having at least 80% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9.

7. (Currently Amended) An isolated peptide having about 11 to 20 amino acid residues and having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9.

8. (Currently Amended) An isolated peptide having about 11 to 20 amino acid residues and having at least 95% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9.

9. (Currently Amended) An isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9.

17. (Canceled)

18. (Canceled)

19. (Currently Amended) An isolated peptide according to claim 1, wherein the peptide is about 15 to 20 amino acids in length.

GTV6436948.1
101668-13

In re Application of:
Albani and Prakken
Application No.: 09/828,574
Filed: April 6, 2001

PATENT
Attorney Docket No.: UCSD1310-1

Title: STRESS PROTEINS AND PEPTIDES AND METHODS OF USE THEREOF
PENDING CLAIMS

21. (Currently Amended) An isolated peptide according to claim 1 that contains a conservative amino acid substitution at least one amino acid position in the peptide.

25 - 32 (Cancelled)

33. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier and an isolated peptide according to claim 1.

38. (Currently Amended) A composition according to claim 33, wherein the isolated peptide has an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 7, 8, and 9.

64. (Currently Amended) An isolated peptide according to claim 1 or 9, wherein the peptide is glycosylated.

67. (Canceled)

68. (Currently Amended) An isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence SEQ ID NO: 6.

69. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier and an isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence of SEQ ID NO: 6.

70. (Canceled)

71. (New) An isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence SEQ ID NO: 2.

72. (New) A composition comprising a pharmaceutically acceptable carrier and an isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence of SEQ ID NO: 2.

In re Application of:
Albani and Prakken
Application No.: 09/828,574
Filed: April 6, 2001

PATENT
Attorney Docket No.: UCSD1310-1

Title: STRESS PROTEINS AND PEPTIDES AND METHODS OF USE THEREOF
PENDING CLAIMS

73. (New) An isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence SEQ ID NO: 3.

74. (New) A composition comprising a pharmaceutically acceptable carrier and an isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence of SEQ ID NO: 3.

GT6436948.1
101668-13

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURRED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLOR OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.